Table II.
patient demographics
| Marfan | BAV | FTAAD | TAAD<50 | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographic Variable | Stat | Male (n=241) | Female (n=217) | p-value | Male (n=390) | Female (n=105) | p-value | Male (n=144) | Female (n=75) | p-value | Male (n=217) | Female (n=60) | p-value | Male (n=992) | Female (n=457) | All (n=1,449) | Adjusted p-value† |
| Mean Age at Enrollment | Mean (SD) | 40.0 (14.1) | 40.7 (14.1) | 0.6 | 50.9 (13.9) | 50.6 (13.2) | 0.85 | 49.1 (13.5) | 49.1 (15.6) | 0.98 | 42.9 (11.3) | 42.2 (12.0) | 0.7 | 46.2 (14.1) | 44.6 (14.6) | 45.7 | ns |
| Mean Age at Dx | mean (std) | 20.8 (15.1) | 19.1 (15.6) | 0.28 | 42.2 (18.3) | 42.8 (17.4) | 0.79 | 41.0 (15.3) | 43.1 (15.5) | 0.35 | 37.3 (11.2) | 35.6 (11.3) | 0.29 | 36.0 (17.9) | 30.9 (19.1) | 34.4 | 0.003 |
| Am. Indian | n(%) | 2 (0.8) | 1 (0.5) | 0.92 | 1 (0.3) | 1 (10) | 0.17 | 0 | 0 | 0.28 | 0 | 0 | 0.52 | 3 (0.3) | 2 (0.4) | 5 | |
| Asian | n(%) | 6 (2.5) | 4 (1.8) | 10 (2.6) | 2 (1.9) | 2 (1.4) | 0 | 10 (4.6) | 3 (5.0) | 28 (2.8) | 9 (2.0) | 37 | |||||
| Black | n(%) | 11 (4.6) | 12 (5.5) | 6 (1.5) | 3 (2.9) | 8 (4.8) | 1 | 26 (12.0) | 11 (18.3) | 51 (5.1) | 27 (5.9) | 78 | |||||
| Pac Island | n(%) | 0 | 0 | 0 | 1 (1.0) | 1 (0.7) | 2 (2.7) | 0 | 0 | 1 (0.1) | 3 (0.7) | 4 | ns | ||||
| White | n(%) | 217 (90.0) | 197 (90.8) | 365 (93.6) | 94 (89.5) | 127 (88.2) | 67 (89.3) | 167 (77.0) | 44 (73.3) | 876 (88.3) | 402 (88.0) | 1,278 | |||||
| Unknown | n(%) | 5 (2.1) | 3 (1.4) | 8 (2.1) | 4 (3.8) | 6 (4.2) | 5(6.7) | 14 (6.5) | 2 (3.3) | 33 (3.3) | 14 (3.1) | 47 | |||||
| Mean BSA (m2) | mean (std) | 2.22 (0.27) | 1.91 (0.21) | <0.001 | 2.06 (0.25) | 1.80 (0.21) | <0.001 | 2.09 (0.25) | 1.82 (0.23) | <0.001 | 2.12 (0.25) | 1.77 (0.19) | <0.001 | 2.12 (0.26) | 1.85 (0.22) | 2.03 | 0.003 |
| Hypertension (Yes) | n(%) | 23 (9.5) | 19 (8.8) | 0.77 | 99 (25.4) | 28 (26.7) | 0.79 | 29 (20.1) | 15(20.0) | 0.98 | 65 (30.0) | 23 (38.3) | 0.22 | 216 (21.8) | 85 (18.6) | 301 | ns |
| CVD/MI | n(%) | 5 (3.2) | 6 (3.9) | 0.76 | 30 (12.1) | 3 (4.8) | 0.1 | 9 (9.1) | 3 (7.3) | 0.72 | 10 (9.0) | 3 (8.1) | 0.87 | 54 (8.8) | 15 (5.1) | 69 | ns |
| Diabetes | n(%) | 12 (5.0) | 6 (2.8) | 0.18 | 20 (5.1) | 5 (4.8) | 0.98 | 7 (4.9) | 1 (13) | 0.3 | 12 (5.5) | 1 (1.7) | 0.38 | 51 (5.2) | 13 (2.8) | 64 | ns |
| Medication (any) | n(%) | 224 (93.0) | 185 (85.3) | 0.01 | 347 (89.0) | 91 (86.7) | 0.51 | 122 (84.7) | 61 (81.3) | 0.32 | 183 (84.3) | 52 (86.7) | 0.66 | 876 (88.3) | 389 (85.1) | 1,265 | ns |
| Beta-Blocker | n(%) | 208 (86.3) | 175 (80.7) | 0.1 | 283 (72.6) | 77 (73.3) | 0.87 | 110 (76.4) | 53 (70.7) | 0.36 | 158 (72.8) | 44 (73.3) | 0.94 | 759 (76.5) | 349 (76.4) | 1,108 | ns |
| Losartan | n(%) | 87 (36.1) | 69 (31.8) | 0.33 | 29 (7.4) | 8 (7.6) | 0.95 | 26 (18.1) | 16 (21.3) | 0.56 | 30 (13.8) | 6 (10.0) | 0.44 | 172 (17.3) | 99 (21.7) | 271 | ns |
| Other ARB | n(%) | 21 (8.7) | 10 (4.6) | 0.08 | 38 (9.7) | 16 (15.2) | 0.11 | 17 (11.8) | 9 (12.0) | 0.97 | 20 (9.2) | 4 (6.7) | 0.53 | 96 (9.9) | 39 (8.5) | 135 | ns |
| ACE-Inhibitor | n(%) | 49 (20.3) | 29 (13.4) | 0.05 | 143 (36.7) | 23 (21.9) | 0.005 | 41 (28.5) | 15 (20.0) | 0.17 | 69 (31.8) | 19 (31.7) | 0.99 | 302 (30.4) | 86 (18.8) | 388 | 0.003 |
| Verapamil/Diltiazem | n(%) | 31 (12.9) | 19 (8.8) | 0.16 | 13 (3.3) | 6 (5.7) | 0.26 | 9 (6.3) | 4 (5.3) | 0.79 | 4 (1.8) | 6 (10.0) | 0.003 | 57 (5.8) | 35 (7.7) | 92 | ns |
| Other Ca+ Channel | n(%) | 32 (13.3) | 15 (6.9) | 0.03 | 49 (12.6) | 16 (15.2) | 0.47 | 24 (16.7) | 12 (16.0) | 0.9 | 50 (23.0) | 9 (15.0) | 0.18 | 155 (15.6) | 52 (11.4) | 207 | ns |
| HMG-Coa | n(%) | 32 (13.3) | 21 (9.7) | 0.23 | 153 (39.2) | 33 (31.4) | 0.14 | 44 (30.6) | 22 (29.3) | 0.85 | 66 30.4) | 14 (23.3) | 0.28 | 295 (29.7) | 90 (19.7) | 385 | 0.003 |
†
Holm-Bonferroni test